Atlas Venture Life Science Advisors, LLC Q4 2025 Filing
Filed February 13, 2026
Portfolio Value
$865.2B
Holdings
8
Report Date
Q4 2025
Filing Type
13F-HR
All Holdings (8 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | KYMRKymera Therapeutics, Inc. | 4,659,874 | $362.6B | 41.91% | |
| 2 | DYNDyne Therapeutics, Inc. | 9,130,465 | $178.6B | 20.64% | |
| 3 | SIONSionna Therapeutics, Inc. | 2,995,602 | $123.2B | 14.24% | |
| 4 | IRONDisc Medicine, Inc. | 1,513,875 | $120.2B | 13.90% | |
| 5 | DAWNDay One Biopharmaceuticals, Inc. | 6,412,560 | $59.8B | 6.91% | |
| 6 | KRROKorro Bio, Inc. | 1,137,149 | $9.1B | 1.05% | |
| 7 | QTTBQ32 Bio, Inc. | 2,092,106 | $6.9B | 0.80% | |
| 8 | GBIOGeneration Bio, Co. | 827,946 | $4.7B | 0.54% |